WATERTOWN, Mass.--(BUSINESS WIRE)--Dicerna Pharmaceuticals, Inc., a second generation RNA interference (RNAi) company developing novel therapeutics utilizing its proprietary Dicer Substrate Technology™ and dicer substrate RNA (DsiRNA) molecules, today announced the presentation of data at the “Oligonucleotide Therapeutics – From Concept to Implementation” Conference, as part of IBC USA’s Drug Discovery & Development Week, being held in Boston from August 3 – 6, 2009. On Tuesday, August 4, at 11:45 a.m., a presentation titled “A Novel Dual Inhibitory Function Anti-HIV Envelop Aptamer-siRNA Chimera,” will be presented by John J. Rossi, Ph.D., Lidow Family Research Chair and Professor in the Division of Molecular Biology, and Dean of the Graduate School of Biological Sciences at City of Hope’s Beckman Research Institute, and scientific co-founder of Dicerna.
